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Cardiac disease is a leading cause of morbidity and mortality in dogs and humans, with dilated cardiomyopathy being a large
contributor to this.The IrishWolfhound (IWH) is one of themost commonly affected breeds and one of the few breeds with genetic
loci associated with the disease. Mutations in more than 50 genes are associated with human dilated cardiomyopathy (DCM), yet
very few are also associated with canine DCM. Furthermore, none of the identified canine loci explain many cases of the disease
and previous work has indicated that genotypes at multiple loci may act together to influence disease development. In this study,
loci previously associated with DCM in IWH were tested for associations in a new cohort both individually and in combination.
We have identified loci significantly associated with the disease individually, but no genotypes individually or in pairs conferred
a significantly greater risk of developing DCM than the population risk. However combining three loci together did result in the
identification of a genotype which conferred a greater risk of disease than the overall population risk. This study suggests multiple
rather than individual genetic factors, cooperating to influence DCM risk in IWH.
1. Introduction
Dilated cardiomyopathy (DCM) is the most common cause
of cardiac death in Irish Wolfhounds (IWH) [1, 2]. In human
DCM there is often a heritable genetic basis of this disease
[3, 4]. In several dog breeds, including IWH, canine DCM
has been shown to have heritable component [5–7]. The
heritability of canine DCM and its clinical resemblance to
human DCM suggest that there is also a genetic basis to
canine DCM [8, 9]. The IWH is a rare, giant breed of dog
and it is considered to be vulnerable by the UK kennel club
due to the small number of annual puppy registrations [10].
IWHs are not long lived with amedian age at death in the UK
population reported to be 7.04 years and amaximumreported
age of 11.83 years [11]. In the same survey of 165 other breeds,
only 14 had a lower median age at death than the IWHs and
most were large or giant breeds. There were 71 breeds with a
median age at death higher than the IWHmaximum reported
age at death [11].
There are a number of health problems reported to occur
frequently in the IWH breed and may contribute to the low
median age at death. These include heart disease, osteosar-
coma, bronchopneumonia, and gastric dilation-volvulus [1,
12–14]. Canine osteosarcoma often results in euthanasia due
to poor quality of life in affected dogs and survival following
diagnosis is typically less than one year [12, 15, 16]. In
contrast, the prognosis of dogs with heart disease such as
atrial fibrillation or DCM is better when diagnosed and
treated early with median time to death reported to be up
to 4 years following early heart disease diagnosis [17]. There
is limited literature on pneumonia in IWH [18, 19] but
Greenwell and Brain [13] reported a breed predisposition
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compared to other breeds treated for pneumonia within a
specialist small animal hospital. The majority (88.9%) of
these initial cases were successfully treated, although 44%
were ultimately euthanized due to recurrent pneumonia
[13]. Although treatable, gastric dilation-volvulus is often life
threatening, with reported mortality rates between 20.5%
and 30% across all breeds [20, 21]. Osteosarcoma and heart
disease are the most likely causes of death or euthanasia
but increased incidence of pneumonia and gastric dilation-
volvulus relative to other breeds also lower the median lifes-
pan of IWH [1, 12–14]. Cardiac disease is the most common
specific reported cause of death in IWH, thus improving the
prevention and diagnosis, and treatment of cardiac disease is
likely to have the greatest impact on improving longevity and
welfare in the breed [22].
There have been several studies investigating the genetic
basis of canine DCM but despite this, very few genetic
associations have been identified [8, 23–26]. Possible reasons
for the lack of identified genetic associations include the
use of inappropriate control populations, incomplete clinical
characterisation of control and affected populations, inade-
quate samples sizes, or an assumption of simple- Mendelian
inheritance, despite the evidence suggesting more complex
multifactorial influences on heritability [5]. Inappropriate
controls have included unaffected individuals from different
breeds to the affected individuals, or young individuals that
still have the potential to develop disease [27–29]. Many
canine DCM studies have also been limited by small sample
sizes of between 5 and 40 individuals, which is unlikely to
be sufficient to detect genetic associations [30]. Furthermore,
our previous studies have shown that multiple loci likely
cooperate to influence canine DCM development; thus com-
binations of genetic factors should be examined together as
well as individually for associations with disease [31]. It is
also important to note that different breeds can have differing
aetiologies and thus may also have differing genetic associa-
tions or causes.This current study utilises the largest recorded
number of affected IWH combined with appropriately aged
unaffected breed-matched controls and examines multiple
loci for an association with canine DCM together as well as
individually.
In addition to commonly being diagnosed with DCM,
IWHs are frequently diagnosed with atrial fibrillation (AF)
[2, 32]. Despite the presence of AF in a large percentage of
dogs with DCM, the mechanistic and clinical relationship
between DCM and AF has not been clarified [2, 32–34].
Although AF is not associated with the development of DCM
in people, the presence of AF in people with DCM and heart
failure has been shown to negatively influence survival [35,
36]. IWH can develop DCM without AF, though it seems
that <2% of IWHs with AF do not go on to develop DCM
[2, 32]. If AF is a potential precursor to DCM, the time
from diagnosis of AF to DCM is important; if it is several
years then the presence of AF could be less of a concern
than if it is merely a few months. Also if AF is a precursor
to DCM there is the potential to give individuals diagnosed
with AF drugs such as the phosphodiesterase III/calcium
sensitizing drug, pimobendan, to improve survival [17]. In
addition to the potential clinical implications of AF diagnosis
and potential early interventions for both dogs and humans, if
AF can be shown to be related toDCM for genetic association
testing, this diagnosis can be used to test for associated DCM
genetic implication.This also has implications for individuals
included in the unaffected group for genetic association
testing; individuals included in the unaffected group must be
free of both DCM and AF.
There is evidence that DCM affects males more often
and/or earlier in life than females [32, 34, 37, 38]. Previ-
ous IWH DCM genetic association studies have either not
reported the age of their unaffected IWHs or used arbitrary
ages to define the unaffected control group [23, 28, 39].
Brownlie and Cobb [32] found a difference between the sexes
in the age of onset ofDCMin IWH in 39 individuals. If the age
of onset differs between males and females, the age at which
an unaffected individual can be included in the unaffected
group for genetic association studies should also be different
for males and females. If DCM affects males more often than
females or there are differences in the age of onset this raises
important questions as to why there might be a difference
between the sexes in age or frequency of onset. This study
therefore also aims to confirm whether there is a sex effect
and/or age of onset differential in relation to DCM in the
IWH.
In this study, we statistically tested the relationships
between DCM and AF, sex differences in disease prevalence
and age of onset, and the use of multiple genetic loci to
establish genetic associations in IWHs. The hypothesis that
AF is associated with DCM in IWHs was tested by estab-
lishing how many individuals diagnosed with DCM were
also diagnosed with AF and how long an individual can
have a diagnosis of AF prior to being diagnosed with DCM.
Individuals diagnosedwithAF, but notDCM,were also tested
to establish whether they had AF diagnosed for a longer
period of time on average than individuals which subse-
quently developed DCM. The second hypothesis was that
male IWHs were diagnosed with both DCM and AF more
frequently than females and secondary to that, the combined
incidence of both disorders was higher inmales than females.
In addition, the hypothesis that the age of onset of DCM
and AF was different in males as compared to females was
tested. Therefore, the age at which an individual can be
considered unaffected was established for males and females.
The fourth hypothesis tested was whether multiple loci could
act together to cause DCM; thus examining loci individually
may not yield significant results [31]. In cases where a
locus is associated with DCM, the result may not have
clinical implications; for example, a locus may be associated
with disease, but only explaining a small number of cases.
However, the examination of multiple loci in combination
could improve the reliability and clinical value of genetic
associations. The hypothesis that genotypes at multiple loci
more comprehensively predict incidences of DCM and
AF than individual loci alone was tested by genotyping
multiple loci putatively associated with IWH DCM and
testing for associations at loci both individually and in
combination.
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Figure 1: Study cohort.
2. Methods
2.1. Samples and Health Updates. This study was approved
by the University of Nottingham ethics committee ethical
number 1823 160714 in compliance with the HomeOffice reg-
ulations and the Veterinary Surgeons Act. Informed consent
was obtained from all dog owners involved in this research.
Buccal swabs from 379 IWHs were taken using Isohelix DNA
Buccal Swabs (Cell Projects Ltd. UK). The swab was inserted
into the dog’s mouth by either the owner, vets, or trained
members of the research group and gently rubbed on the
cheek for up to 2 minutes to enable optimum cell collection.
Swabs were stored as directed by the manufacturer, at room
temperature upon collection followed by 4∘C. Any swabs
stored for longer than a month prior to DNA extraction
were stored at −20∘C. Optimisation trials indicated that
appropriate quality and quantity of DNA could be obtained
following all storage methods. When the buccal swabs were
taken owners completed a short information sheet for each
dog in order to obtain current and past health information,
date of birth, pedigree information, sex, and neutering status.
All information was associated with a unique sample number
and stored in a secure excel database.
Follow-up data on the health of DNA-sampled dogs was
obtained at numerous time points. Owners were asked to
fill in a “health update” form annually or following any
change in health/upon death. Forms could be completed
either online or in paper format to ensure maximum owner
participation. In addition, telephone surveys were carried out
on this longitudinal health study. The surveys were utilised
to obtain health updates and epidemiology data on all
dogs from which samples had been obtained. Many IWH
are presented to veterinary cardiologists on a regular basis
for heart disease screening. These heart screenings consist of
cardiac auscultation, a six-lead electrocardiogram, and com-
plete echocardiographic assessment. Data from these heart
screenings were provided by veterinary cardiology specialist
Dr. Serena Brownlie. Cardiac diagnoses were determined
by Professor Malcolm Cobb based on the data from heart
screenings. Information fromowner health updates and heart
screenings was analysed alongside genetic data.
2.2. DCM and AF Relationship. Individuals diagnosed with
DCM, AF, and both DCM and AF in the database were iden-
tified, and the numbers in each diagnosis category “DCM,”
“AF,” and “DCM and AF” were determined (Figure 1). In the
subset of individuals with both DCM and AF, the time from
AF diagnosis to DCM diagnosis was established based on the
dates of the heart screenings at which each was diagnosed.
Individuals that were diagnosed with AF, but not DCM, had
the time with AF determined by the time between the first
heart screening that AF was diagnosed at and themost recent
heart screening. A 𝑡-test was performed to establish if the
time from AF diagnosis to DCM diagnosis was significantly
different from the time that individuals had been known to
have a diagnosis of AF, but not DCM.
2.3. Sex Differences in Numbers Affected and Age of Disease
Onset. The number of males and females diagnosed with
DCMor AFwas established from the database along with the
number of males and females not diagnosed with DCM or
AF. A 𝜒2 test was performed to establish whether there were
differences in the number of males and females diagnosed
withDCMorAF.The age at first diagnosis of DCMorAFwas
established for all individuals diagnosed with either disorder.
A 𝑡-test was performed to identify statistical differences
between males and females at age of diagnosis. The data
was also displayed visually in bar plots generated using R
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statistical software. In addition, a 𝜒2 test was performed to
establish whether there were differences in the number of
males and females affected which had been neutered or not
neutered.
2.4. Genetic Associations
2.4.1. DNA Extraction and Restriction Fragment Genotyping.
To extract DNA from buccal swabs, the end of the swab
was first cut into small pieces using scissors which were
sterilised between swabs using Anistel (Tristel, UK) and
then wiped down with Industrial Methylated Spirits (IMS;
Thermo Fisher Scientific, USA). The small pieces of swab
were put into a sterile 1.5mL microcentrifuge tube (Eppen-
dorf, Germany). The DNA-containing swab fragments were
resuspended in 600 𝜇L of a solution composed of 5% sodium
Chelex 50–100mesh (dry; Sigma-Aldrich, USA) reconsti-
tuted in 1x TE (10mM Tris (Thermo Fisher Scientific, USA),
1mM EDTA (Thermo Fisher Scientific, USA) in H2O, pH
8.0) and 20𝜇L of 10mg/mL proteinase K (Promega, USA),
50mM Tris (Thermo Fisher Scientific, USA), and 10mM
CaCl2 (Thermo Fisher Scientific, USA), pH 8.0. The sample-
containing microcentrifuge tube was vortexed to mix the
components. The microcentrifuge tube was then placed in a
water bath at 45∘C overnight to digest the cells. The sample
was then vortexed once more before incubation in a heating
block at 100∘C for 8 minutes to inactivate the proteinase K.
The sample was then centrifuged at 13,500×g for 3 minutes
to separate the Chelex and swab from the supernatant. The
DNA-containing supernatantwas then transferred into a ster-
ile 1.5mL microcentrifuge tube and was used in subsequent
PCRs. The extracted DNA was then stored at −20∘C in the
Nottingham Comparative Genomic Biobank.
Restriction digests were used to genotype SNPs previ-
ously shown to be associated with DCM [23], in the Notting-
ham IWH cohort. In the first instance the effect of the SNPs
on restriction sites within the affected loci was examined.
PCR primers were designed to flank five DCM-associated
SNPs which alter restriction sites. Where the SNP did not
alter or create a restriction site, PCR primers were designed
to introduce a restriction site into the PCR product to detect
the presence/absence of the SNP. Primer information and
fragment size amplified are presented in Table 1. Primers
were obtained from Sigma-Aldrich, UK.The SNPs are hereby
referred to as Chr1 for rs21953123, Chr10 for rs22078677,
Chr15 for rs22422063, Chr21 for rs22923291, and Chr37 for
rs24025150.
The PCR reaction mixture consisted of the following: 1x
LightCycler 480 Probes Master Mix (Roche, Switzerland),
primers at a concentration of 0.5𝜇M, and between 2 and 4 𝜇L
of template DNA per reaction, adjusted to 25 𝜇L using PCR
grade H2O. Where PCR reactions initially failed, increased
template DNA was used (up to 4 𝜇L) and the amount of H2O
in the reaction was reduced accordingly. PCR reactions were
carried under the following conditions: Initial denaturation
94∘C for 30 seconds, 40 cycles of 94∘C for 30 seconds, anneal-
ing temperature for 30 seconds, 72∘C for 30 seconds, and
final extension 72∘C for 5minutes.The annealing temperature
optimisation was determined by performing a temperature
gradient PCR between 52∘C and 64∘C (see Table 2).
Restriction digests were conducted on each PCR product.
The reaction mixture for each restriction digest consisted
of 3 𝜇L of 10x buffer, 20𝜇L PCR product, and 1–6 units of
enzyme in a reaction volume of 30 𝜇L.The enzyme manufac-
turer provided the appropriate buffer for each enzyme and the
stated activation temperature; the number of units of enzyme
was optimised for restriction digest reaction. The details for
each restriction digest are shown in Table 3. The restriction
digests were performed by incubating the reactionmixture at
the activation temperature of enzyme for 14 hours.
Following digestion, the digested PCR products were
electrophoresed at 100 v for 45mins on 2% agarose 1x TAE
gels stained with Nancy-520 (Sigma-Aldrich, USA) in 1x TAE
buffer. A DNA size ladder (𝜙x-HaeIII fragments) purchased
fromNEBwas used to determine the size of the digested PCR
fragments. Genotypes were determined by the restriction
digestion fragment pattern based on the presence of an
appropriate restriction site determined by the presence of the
SNP, with the possibility of detecting homozygotes (AA, aa)
and heterozygotes (Aa). Presumptive homozygotes for each
genotype (AA, aa) were confirmed by direct Sanger sequenc-
ing of representative PCR fragments (Source BioSciences,
Nottingham). For all loci a single band, the same size as the
PCR product, showed that none of the PCR product had been
digested and was genotyped as a homozygote for the allele
that does not digest. The absence of this larger band and
the presence of smaller bands at the expected sizes following
digestion (Table 1) showed that all of the PCR product
had been digested so these were genotyped as homozygotes
for the allele that was digested by the restriction enzyme.
Those with a band the same size as the PCR product plus
bands at the expected sizes following successful digestion in
Table 1 were genotyped as heterozygotes. These genotypes
were manually recorded within a database alongside appro-
priate sample numbers and clinical information. One sample
of each genotype at each SNP was confirmed by Sanger
sequencing by Source Bioscience (Nottingham, UK).
2.4.2. Analysis. To establish whether the population within
this study genetically resembled the published data by Philipp
et al. [23], the allele frequencies at each locuswere determined
in the entire sampled population irrespective of age or
disease status. These allele frequencies were compared to the
published allele frequencies at the same loci.
All individuals with a diagnosis of DCM or AF were
included in the affected group. As outlined in the results and
Figure 2, males were shown to be affected by DCM and AF
at an age earlier than females. For this reason, females were
considered to be unaffected if they had not been diagnosed
with eitherDCMorAF at a heart test after the age of 8.5 years.
Males were considered unaffected if they had reached the age
of 6.5 years and had a heart test without a diagnosis of DCM
or AF. All affected animals were included regardless of age.
The number of individuals expected to develop DCM
under four common penetrance models for each SNP was
obtained by methods described by Camp [40]. The observed
risk of disease for each genotype was obtained directly from
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Table 2: PCR annealing temperatures as determined by temperature
gradient PCR optimisation for each primer pair.
SNP Primer pair Annealingtemperature
Chr1: rs21953123 C/T All primer pairs 52∘C
Chr10: rs22078677 A/C
Initial primers 60∘C
Initial forward primer,
new reverse primer 52
∘C
Chr15: rs22422063 C/A All primer pairs 52∘C
Chr21: rs22923291 G/A
Initial primers 58∘C
New forward primer,
initial reverse primer 52
∘C
Chr37: rs24025150 G/A
Initial primers 58∘C
Initial forward primer,
new reverse primer 52
∘C
Male
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Figure 2: Cumulative percentage of individuals diagnosed with
DCM or AF at or before each age category. Males (blue) and females
(red) are shown separately.
the data by dividing the number of each genotype affected
by the total number of individuals with the genotype. The
genetic penetrance parameter (𝛾) was then established for
each SNP. For the multiplicative, additive, and dominant
models, 𝛾 indicates the relative risk of the heterozygote
genotype compared to the homozygote genotype with the
lowest risk; for the recessive model it indicates the relative
risk of the most at risk homozygote compared to the least at
risk homozygote. The penetrance parameter was then used
to calculate the proportion of each genotype expected to
develop disease under each model. Table 4 shows how the
penetrance parameter was used with the lowest homozygote
risk under each model to calculate these proportions.
The proportion of each genotype expected to develop dis-
ease under each model was then translated into the number
expected by multiplying the proportion by the total number
of individuals observed with the genotype, irrespective of
disease status. A 𝜒2-squared test was performed to establish
which model of penetrance most closely fitted the observed
data.Themodel with the smallest𝜒2-squared value was taken
to be the best fit of the observed data.
Having established the model of penetrance, the most
appropriate test for association with disease was then carried
out. Where A is the disease associated allele, for dominant
models the counts for individuals which genotyped as a/A
and A/A can be pooled as the penetrance is equivalent;
similarly for recessivemodels the counts for individuals geno-
typed as a/a and a/A can be pooled [41]. For multiplicative
models allelic tests of association are more powerful [41].
Additive models are most appropriately tested by a Cochran-
Armitage trend test, or genotype association testing [41]. To
test for association with disease 𝜒2 tests were performed.The
expected numbers of affected individuals with each genotype
or allele were obtained by establishing the proportion of
unaffected individuals with each genotype or allele. These
proportions of unaffected individuals with each genotype or
allele were then multiplied by the total number of affected
individuals to establish the expected number of affected
individuals with each genotype. To account for multiple tests
a Bonferroni correction was applied to the 𝑝 values.
To establish whether particular genotypes gave an
increased risk compared to the overall population risk, rela-
tive risks were calculated alongside 95% confidence intervals.
Relative risks were calculated by dividing the genotype risk
with the population risk and 95% confidence intervals were
calculated using the methods in [42]. Where appropriate,
genotypes were combined, for example, where the penetrance
model was shown to be recessive or dominant, or where there
were less than 5 total individuals with a genotype.
To establish whether using multiple loci to test for an
association could increase the association compared to indi-
vidual loci alone, each significant locus was considered with
each of the other significant loci in pairs and all combined.
For this analysis the expected numbers were calculated
and tested for an association in the same way as for loci
individually. Risks of disease for each genotype combination
were also established and relative risks calculated in the same
way as individual loci.
3. Results
3.1. DCMandAFRelationship. Therewere 36 individual dogs
diagnosed with DCM included in the current study (from a
total of 379 genotyped individuals, 9.50%, Figure 1) and 29
(80.5%) DCM affected individuals also had a diagnosis of
AF. In total, 17 of the 29 (58.6%) were diagnosed with DCM
and AF at the same time, whereas the remaining 12 had been
diagnosed with AF prior to the DCM diagnosis. Of the 12
that had been diagnosed with AF prior to DCM, 11 (91.7%)
had been diagnosed with AFwithin 2 years, and all hadDCM
diagnosed within 3 years of their first AF diagnosis.
In the current study, there were additional 36 individuals
(from a total of 379 genotyped individuals, 9.50%) that had
been diagnosed with AF, but not DCM. Of these individuals
24 (66.7%) had not been presented for heart disease screening
since diagnosis. Only 7 (19.4%) had only been tested within
1 year of their original diagnosis of AF. Further 4 individuals
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Table 3: Restriction digest information.
SNP Enzyme Units of enzymeper reaction Restriction site Cuts allele Primer pair
Digest
fragment
sizes
Chr1: rs21953123 C/T HpyCH4II(NEB, USA) 3 ACTGT C
Original primers 228 & 83
New primers 260 & 157
Chr10: rs22078677 A/C BanI (NEB,USA) 6 GgCACC C
Original primers 19 & 355
Original forward primer, new
reverse primer 19 & 142
Chr15: rs22422063 C/A NciI (NEB,USA) 6 CCCGG C
Original primers 196 & 179
Original forward primer, new
reverse primer 227 & 216
Chr21: rs22923291 G/A Fnu4HI (NEB,USA) 1 GCTGc G
Original primers 310 & 39
New forward primer, original
reverse primer 384 & 39
Chr37: rs24025150 G/A HpaII (NEB,USA) 3 cCGG G
Original primers 28 & 346
Original forward primer, new
reverse primer 28 & 105
Enzymes, restriction sites, primer pairs, and digest fragment sizes for each SNP.
Table 4: The relationship of the risk of disease with the penetrance
parameter.
Model Penetrance
a/a a/A A/A
Multiplicative 𝑓0 𝑓0𝛾 𝑓0𝛾
2
Additive 𝑓0 𝑓0𝛾 2𝑓0𝛾
Recessive 𝑓0 𝑓0 𝑓0𝛾
Dominant 𝑓0 𝑓0𝛾 𝑓0𝛾
Risk of disease (𝑓0) of the least risky homozygote (a/a) is related to the
genetic penetrance parameter (𝛾) for each additional genotype under mul-
tiplicative, additive, recessive, and dominant models. For the multiplicative,
additive, and dominant models 𝛾 is the relative risk of the heterozygote
genotype compared to the homozygote genotype with the lowest risk; for
the recessive model it is the relative risk of the most at risk homozygote
compared to the least at risk homozygote.
(10.8%) had been tested within 2 years of original diagnosis
and one individual had been tested 2.5 years following AF
diagnosis. In total, heart disease screening data and DNA
samples were taken across a ten-year period.
The time from AF diagnosis to DCM diagnosis in the
group of individuals diagnosed with both AF and DCM was
not significantly different from the time individuals only
diagnosed with AF had been known to have a diagnosis of
AF (𝑡 = 0.56, 𝑝 = 0.58).
3.2. Sex Differences in Numbers Affected and Age of Disease
Onset. It was noted that there was no difference in observed
and expected numbers of affected cases in either males or
females (𝑛 = 191 entire females and 66 neutered females, with
28 and 16 affected, resp. 𝑛 = 116 entire males and 25 neutered
males with 16 and 7 affected resp. 𝑡 = 2.63 for females and
2.54 for males, 𝑝 > 0.05).
Individuals with diagnoses of DCM and AF were
included in the affected group. There was no difference in
the proportion of males and females affected by DCM/AF
combined, 𝜒2-squared test result = 0.13 (𝑝 = 0.72, df = 1).
There was a significant difference between males and females
in the age of diagnosis of DCM/AF combined. DCM/AF
combinedmean age at diagnosis was 4.82 years for males and
6.14 years for females (𝑡 = 2.43, 𝑝 = 0.019). Of males that
developed AF or DCM, 80% had done so before the age of
6.5 years, while 80% females that developed AF or DCM did
so before the age of 8.5 (Figure 2). Using these age restric-
tions in the sample cohort there were 9 females unaffected
by either diagnosis over the age of 8.5 years and 14 males
unaffected over 6.5 years. Of the individuals not included
in the DCM/AF affected group or the unaffected group, 20
were known to have died of causes other than DCM or AF
before reaching the age restrictions, 234 had not reached the
age restrictions, and 27 were over the age restriction but had
not been heart tested since reaching the age restriction, and
3 were of unknown age. Using the information above, it was
therefore possible to define the “unaffected” groupwith a high
level of stringency and specificity, in addition to enhancing
the knowledge on sex related differences in age of clinical
diagnosis.
Within the study cohort (Figure 1), 23 (34.7%) individuals
were diagnosed with DCM or AF at their first heart test
and of these, 19 (82.6%) were less than 6.5 years old. Of the
4 that were over 6.5 years old at first diagnosis without a
previous heart test 1 was male and 3 were female. Due to the
uncertainty in the age that these older individuals would have
developed the condition, these individuals were removed
from the age of onset analysis to ensure that these do not
skew the difference in age of onset between the sexes. The
𝑡-test result excluding these individuals remained significant
at the 5% threshold level (𝑡 = 2.11, 𝑝 = 0.040), which was
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Table 5: Allele frequencies at each SNP in the data published in
Philipp et al. [23] and the current study.
Allele Published allele frequency Current study allele frequency
Chr1 C 0.88 0.82
Chr1 T 0.12 0.18
Chr10 A 0.94 0.94
Chr10 C 0.06 0.06
Chr15 C 0.74 0.63
Chr15 A 0.26 0.37
Chr21 G 0.71 0.58
Chr21 A 0.29 0.42
Chr37 G 0.57 0.59
Chr37 A 0.43 0.41
Chr1 refers to the SNP on chromosome 1, Chr10 the SNP on chromosome
10, and so forth, as identified in Philipp et al. [23] and Table 1.
comparable to when those individuals were included within
the dataset.
3.3. Genetic Associations. The individuals in the current study
were primarily from the UK IWH population, while those
in the study by Philipp et al. [23] were from mainland
Europe. Despite the use of a different subpopulation of IWHs
there was a general concordance between the published allele
frequencies and those in the current study (Table 5). The
alleles at the SNPs on chromosomes 1, 10, and 37 were within
0.1 of the published frequencies. The alleles at the SNPs
on chromosomes 15 and 21 were close to within 0.1 of the
published frequencies.
The mode of penetrance was established to be multigenic
for the SNPs on chromosomes 1 and 10: dominant for the
chromosome 15 and 21 SNPs and recessive for the SNP on
chromosome 37 (Table 6). This allowed allelic association
tests to be performed for the SNPs on chromosomes 1 and
10, the numbers of individuals genotyped as AA and AC for
SNP on chromosome 15 to be combined, and the numbers
of individuals genotyped as GA and GG for the SNPs on
chromosomes 21 and 37 to be combined; thus the number of
degrees of freedom for each association test was reduced to
one (Table 6).
Three loci had significant associations with DCM/AF
combined, specifically the SNPs on chromosomes 1, 21, and
37 (Table 6). The risks of developing DCM or AF for each
genotype are presented in Table 7, along with the total
numbers of individuals with each genotype. There were very
few individuals genotyped as TT at the chromosome 1 locus,
CC was the highest risk allele, and allelic association tests
established that the C allele was associated with DCM/AF;
therefore the numbers of TT individuals were combined
with the CT individuals. Chromosome 21 and 37 SNPs were
determined to be dominant and recessive, respectively, so
the GA and GG genotypes were combined at both loci. The
overall risk of developing DCM or AF was 0.76. Several
genotypes gave an elevated risk compared to the overall risk,
and several gave reduced risk, none of these increased or
decreased risks were significantly different from the overall
risk.
Combining genotypes at pairs of loci decreased the
significance of the chromosome 1 SNP but increased the
significance of chromosomes 21 and 37 SNPs (Tables 6 and 8).
Combining all three loci together increased the significance
for all loci (𝜒2-squared value = 41.09, 𝑝 = 0.00000078).
From both the pairs of loci and all three loci combined,
the genotypes with the greatest disease risk were those which
combined the high risk individual genotypes (Tables 8–12). In
particular Chr1 CC, Chr21 GA/AA, and Chr37 AA combined
gave the single highest risk of developing disease and was
significantly higher than the overall population risk. The
opposite was also the case with the lowest combined disease
risk resulting from the combined genotypes of those with
individually the lowest risk, but none gave a significantly
decreased risk compared to the overall population risk. All
other genotype combinations are somewhere in between.
4. Discussion
The data acquired here supports an association between AF
and DCM in IWHs.Themajority (80.5%) of individuals with
DCM also had a diagnosis of AF. Most individuals were
diagnosed with AF at the same time as DCM, or in the 2 years
prior to the diagnosis of DCM, which indicates that AF may
be a precursor to a clinical diagnosis of DCM. The current
results are consistent with a previous study which found
that 87.6% of individuals diagnosed with DCM were also
diagnosed with AF [2]. Further evidence for the relationship
between AF and DCM comes from the time period that
individuals diagnosed only with AF have spent with the AF
diagnosis. The majority (66.7%) had not had a subsequent
heart test and of those that had been retested the longest time
between initial AF diagnosis and most recent heart test was
2.5 years. All individuals with AF alone still had/have the
potential to develop DCM as the time periods with AF were
not longer than the time periods between AF diagnosis and
DCMdiagnosis (𝑡 = 0.56,𝑝 = 0.58).This finding is consistent
with Vollmar [2] in which 11 individuals were diagnosed with
AF, but notDCM;however only 3 individualswere knownnot
to have subsequently developed DCM, with 29 months as the
maximum time with AF alone. This relationship between AF
and DCM allowed for the inclusion of individuals diagnosed
with AF as well as DCM in the affected group for genetic
association tests. In addition, this provides evidence that
individuals diagnosed with AF should be carefullymonitored
and regularly presented for heart testing to ensure that they
do not yet require treatment for DCM. There is also the
potential to improve the survival of individuals diagnosed
with AF by treating them with drugs such as pimobendan
prior to the development of DCM or heart failure [17], in
addition to receiving therapy for AF.
Very few IWHs were unaffected by AF or DCM into old
age (defined as older than the median lifespan of 7.04 years
in IWHs [11]), as most individuals developed one or both
disorders, or they died of other conditions before reaching
old age. As noted earlier, this breed is also susceptible to
osteosarcoma, pneumonia, and gastric dilation-volvulus, all
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Table 6: Mode of penetrance for individual SNPs in relation to IWH DCM/AF.
Chr1 Chr10 Chr15 Chr21 Chr37
Mode of penetrance Multigenic Multigenic A dominant G dominant A recessive
Type of test Allelic Allelic A dominant G dominant A recessive
Chi-squared test result 10.61 5.07 1.52 7.67 11.12
df 1 1 1 1 1
Bonferroni corrected 𝑝 0.0056 0.12 1.00 0.028 0.0043
Published DCM allele C A C A G
Current DCM/AF allele C C A G A
Mode of penetrance, subsequent genetic association test used, chi-squared test result, degrees of freedom of the chi-squared test, and Bonferroni corrected 𝑝
value for each locus. Also shown are the alleles associated with IWH DCM in Philipp et al. [23] and IWH DCM/AF in the current study. Chr1 refers to the
SNP on chromosome 1, Chr10 the SNP on chromosome 10, and so forth, as identified in Philipp et al. [23] and Table 1.
Table 7: Risk of developingDCM/AF for each genotype at loci iden-
tified as significantly associated with DCM/AF.
Genotype Risk Totalgenotype
Risk relative
to population
risk
95% CI
Chr1 CC 0.81 54 1.08 0.91 to 1.28
Chr1 CT 0.68 22 na na
Chr1 TT 0.5 4 na na
Chr1 CT/TT 0.65 26 0.86 0.64 to 1.17
Chr21 AA 0.61 18 0.81 0.55 to 1.19
Chr21 GA 0.77 39 na na
Chr21 GG 0.82 33 na na
Chr21 GA/GG 0.79 72 1.04 0.89 to 1.23
Chr37 AA 0.85 27 1.12 0.93 to 1.36
Chr37 GA 0.70 23 na na
Chr37 GG 0.73 44 na na
Chr37 GA/GG 0.72 67 0.95 0.78 to 1.14
The risk of developing disease for each genotype, the total number of indi-
viduals with each genotype, the relative risk of each genotype compared
to the population risk, and associated 95% confidence intervals. Where
dominant or recessive modes of penetrance were established or less than 5
total individuals had a genotype, genotypes were pooled and these are also
presented. Chr1 refers to the SNP on chromosome 1, Chr21 the SNP on
chromosome 21, and Chr37 the SNP on chromosome 37 as identified in
Philipp et al. [23] and Table 1.
Table 8: Chi-squared test results for the genotype associations with
DCM/AF for pairs of loci.
Chr1+21 Chr1+37 Chr21+37
Chi-squared test result 14.16 15.56 24.55
df 3 3 3
Bonferroni corrected 𝑝 0.0081 0.0042 0.000058
Chi-squared test results, degrees of freedom (df) of the chi-squared tests,
and Bonferroni corrected 𝑝 values for genotype associations. Chr1 refers to
the SNP on chromosome 1, Chr21 the SNP on chromosome 21, and Chr37
the SNP on chromosome 37 as identified in Philipp et al. [23] and Table 1.
of which can require euthanasia [12–14]. This influenced the
number of animals and the age-range in theDCMorAFunaf-
fected control group for genetic association testing. Young
unaffected individuals retain the potential to develop DCM
Table 9:The risk of developing disease for each genotype combina-
tion at chromosomes 1 and 21 loci.
Chr1 Chr21 DCM/AFrisk
Total
genotyped
Risk
relative to
population
risk
95%
CI
CC GG/GA 0.81 48 1.07 0.90 to1.28
CC AA 0.83 6 1.10 0.76 to1.60
CT/TT GG/GA 0.74 19 0.97 0.73 to1.30
CT/TT AA 0.33 6 0.44 0.14 to1.37
Total number of individuals with each genotype combination, the relative
risk of each genotype compared to the population risk, and associated 95%
confidence intervals. The individual genotypes are in bold type if they were
identified as conferring increased risk of disease and normal type if they
were identified as conferring decreased risk of disease.
Table 10: The risk of developing disease for each genotype combi-
nation at chromosomes 1 and 37 loci.
Chr1 Chr37 DCM/AFrisk
Total
genotyped
Risk
relative to
population
risk
95%
CI
CC GG/GA 0.79 38 1.04 0.85 to1.27
CC AA 0.88 16 1.15 0.93 to1.43
CT/TT GG/GA 0.61 18 0.81 0.55 to1.19
CT/TT AA 0.75 8 0.99 0.65 to1.50
Total number of individuals with each genotype combination, the relative
risk of each genotype compared to the population risk, and associated 95%
confidence intervals. The individual genotypes are in bold type if they were
identified as conferring increased risk of disease and normal type if they
were identified as conferring decreased risk of disease.
or AF in the future; thus including these individuals in the
unaffected group would have resulted in misleading genetic
association test results. Ideally, only very aged unaffected
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Table 11:The risk of developing disease for each genotype combina-
tion at chromosomes 21 and 37 loci.
Chr21 Chr37 DCM/AFrisk
Total
genotyped
Risk
relative to
population
risk
95%
CI
AA GG/GA 0.62 13 0.81 0.52 to1.27
AA AA 0.60 5 0.79 0.38 to1.63
GA/GG GG/GA 0.75 52 0.99 0.82 to1.20
GA/GG AA 0.89 19 1.18 0.97 to1.43
Total number of individuals with each genotype combination, the relative
risk of each genotype compared to the population risk, and associated 95%
confidence intervals. The individual genotypes are in bold type if they were
identified as conferring increased risk of disease and normal type if they
were identified as conferring decreased risk of disease.
individuals would have been included in the unaffected group
as the certainty that they have not developed DCM or AF
would have been high. Although this would have reduced
the risk of including an individual in the wrong group,
it would have reduced the sample size of the unaffected
group to below what is required for genetic association
testing. As a compromise the age at which 80% of ultimately
affected individuals were affected was determined and this
age restriction was utilised to determine at what age to allow
an unaffected individual to be included in the unaffected
group. In the present study, the age of disease diagnosis
was established as significantly different between males and
females. Males were diagnosed with DCM/AF on average
younger than females, although individuals of both sexes
were diagnosed from the age of 1.5 years (Figure 2); this
corroborates the findings of Brownlie and Cobb [32]. The
age of 80% of all ultimately AF/DCM affected males was
established as 6.5 years. Females, however, needed to reach
8.5 years before 80% of the individuals that were diagnosed
with AF or DCM had done so. These age restrictions were
used to determine at what age it was practical to assign a
currently unaffected individual to the “unaffected control”
group. Despite the collection of 379 samples across four years,
and the use of unstringent age restrictions, there were only 22
individuals not affected by DCM or AF above these two ages.
Some of the individuals that were not included in either group
had died before reaching the age restrictions, but themajority
(261 individuals) either had not reached the age restriction
by the end of the study, or had not been heart tested since
reaching the age restriction.Therewas a clear difference in the
age of diagnosis between males and females, but the reasons
for this are unknown. It is possible that males were heart
tested earlier and more regularly than females and thus are
overrepresented in earlier diagnoses. The calculations which
involved exclusion of individuals diagnosed over the age of
6.5 years of both sexes which had not previously been heart
tested did not change the significance threshold of the 𝑡-
test determining differences in the age of diagnosis. This
indicated that the differences in the age of diagnosis are
likely to be related to the age of disease onset, not age at
presentation for heart testing. Strong candidates for further
work to investigate these sex differences are hormones which
differ in the amount and ratio between the sexes and the
different responses to these hormones [43–47]. In light of the
differences between males and females, neutering status was
of interest. There was not an overall difference in the number
of affected cases between neutered and nonneutered IWHs
for either males or females; however further investigations
into neutering age could be investigated to show whether this
affects disease onset or progression.
All loci examined for an association with disease had
previously been associated or putatively associated with
DCM in IWHs from mainland Europe by Philipp et al.
[23]. The current study primarily studied IWHs from the
UK and genetic differences between subpopulations of the
breed were possible. While this potential genetic difference
was possible, it was unlikely as mixing of bloodlines occurs
throughout Europe [48]. This was supported by the finding
that allele frequencies were broadly similar in both genotyped
populations across all loci (Table 5). Given the genetic
similarity between the mainland Europe IWH population
and the UK IWH population, genetic associations with
disease in one population should remain in the other, but
this was not the case (Table 6). Only three out of five of
the SNPs previously associated with IWHDCM in mainland
European dogs were associated with DCM/AF in the current
study, and of these only one had the same allele associated
with disease (Table 6) [23]. There are a number of possible
explanations for this apparent inconsistency between studies.
The first is that despite genetic admixture occurring and the
similarity in allele frequencies between populations, there
was unidentified population substructure. Although this is
possible, it is unlikely given the known mixing of bloodlines
and the meticulous record keeping required for prestigious
pedigree breeds such as IWH [48]. More likely explanations
for the discrepancy between populations are the sample
size and age at which unaffected individuals were included
in the unaffected group. Although our study obtained the
largest number of samples in the breed ever collected thus
far and the previous study by Philipp et al. [23] was large
in comparison to many canine genetic studies, for accurate
genotype-phenotype associations to bemade a larger number
of samples are required. Typical human genotype association
studies use over 2,000 individuals, with someusingmore than
10,000 individuals [49–52]. Philipp et al. [23] used a total of
190 individuals, and in the present study 379 DNA samples
were collected but following more stringent inclusion criteria
95 individuals could be included in the genetic association
analysis. The age an individual can be considered healthy for
DCM genetic association purposes varies between breeds,
but it has not previously been based on clear justification
[23, 28, 39]. The analysis in the present study shows the
age that an unaffected male can be included in the healthy
group was younger than an unaffected female (Figure 2).
The age that an unaffected female can be included in the
unaffected group was 8.5 years; the caveat is that, despite
this age restriction, 20% of females that developed DCM or
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Table 12: The risk of developing disease for each genotype combination at chromosomes 1, 21, and 37 loci.
Chr1 Chr21 Chr37 DCM/AF risk Total genotyped Risk relative to population risk 95% CI
TT/CT AA AA 0.50 2 0.66 0.16 to 2.65
TT/CT AA GG/GA 0.25 4 0.33 0.06 to 1.81
TT/CT GA/GG AA 0.80 5 1.06 0.67 to 1.66
TT/CT GA/GG GG/GA 0.73 15 0.97 0.70 to 1.34
CC AA AA 0.50 2 0.66 0.16 to 2.65
CC AA GG/GA 1.00 4 1.32 1.18 to 1.48
CC GA/GG AA 0.93 14 1.23 1.02 to 1.47
CC GA/GG GG/GA 0.76 34 1.01 0.81 to 1.26
Total number of individuals with each genotype combination, the relative risk of each genotype compared to the population risk, and associated 95% confidence
intervals. The individual genotypes are in bold type if they were identified as conferring increased risk of disease and normal type if they were identified as
conferring decreased risk of disease.
AF did so after this age. The study by Philipp et al. [23]
included unaffected individuals of both sexes over the age
of 7 years in the healthy group. In the context of the present
results this was adequate for males, for which 80% of affected
individuals were diagnosed before the age of 6.5 years. In
females, however, over 40% of individuals that developed
disease in the current study did so after 7 years old (Figure 2);
thus the inclusion of females under the age of 8.5 years in
the unaffected group is likely to lead to spurious genetic
associations in the study by Philipp et al. [23]. In addition
the authors did not state whether individuals with AF were
excluded from the unaffected group. Although the current
study only had 23 individuals in the unaffected group, the
genetic associations made are more likely to be correct as
individuals were less likely to be inappropriately included in
the unaffected group based on age or diagnosis of AF.
Individually, three loci were significantly associated with
DCM/AF in the current study, but none of the genotypes
conferred a significant increase or decrease in risk compared
to the overall population risk of disease (Tables 6 and 7).
Combining the significant loci into pairs increased the signif-
icance of the genetic associations and the risk of disease for
the most risky genotype combinations (Tables 8–11). Despite
combining genotypes at pairs of loci, none of genotype
risks were significantly increased or decreased relative to the
population risk.The combination of genotypes from all three
significant loci resulted in a significant genetic association
(𝑝 < 0.0001). Furthermore, the risk of disease in individuals
which had themost risky genotypes at all three loci (Chr1 CC,
Chr21 GA/GG, and Chr37 AA) was significantly increased
compared to the population risk (Table 12). This is consistent
with our previous work which showed that information
from multiple loci combined could be more informative in
predicting disease than individual loci and is the first study
to show that the multiple allele effect is important in canine
heart disease [31].
Genetic associations identify loci and alleles associated
with disease, but to be of relevance to clinicians, breeders,
and owners, there is a need to define genotype combinations
which significantly increase or decrease the risk of developing
disease. Individuals with high risk genotypes can be more
intensively monitored for the early signs of disease. With
heart testing it is possible to detect disease in advance of
overt clinical symptoms and it has been shown that some
drugs can increase the time to progression to overt disease,
thus improving quality of life and longevity [17]. If high risk
genotype combinations can be identified, breeders can reduce
the risk of individuals developing disease by ensuring that
mating will not result in offspring with genotypes with a high
risk of developing disease. The methodology in this study
has the potential to supplement those currently utilised in
establishing genetic risk scores, as it can account for interac-
tions between loci and dominant or recessive alleles [53–56].
The methodology could be applied to a variety of diseases
and traits, and it is not restricted to use in canine disease
so it could thus be of use in human genetic counselling. It
should be noted that breeding programme management for
genetic conditions must be managed carefully to ensure that
prevalence of other genetic diseases does not inadvertently
increase.
There were no genotypes identified which conferred a
significant protective effect, but some genotypes had few (<5)
individuals genotyped irrespective of disease status (Tables
7–12). From so few genotyped individuals it is not realistic
to draw definitive conclusions, but within some of these
genotypes there were more individuals without disease than
with disease. This indicates that these genotypes may confer
a protective effect against the development of DCM/AF
compared to the overall population risk; a greater number
of affected and unaffected individuals would allow this to
be tested. The inclusion of additional individuals could also
reduce the 95% confidence intervals for the relative risks
at other genotypes, potentially allowing genotype combina-
tions with increased, but not high risk to be confirmed.
Increasing the number of individuals genotyped may allow
for more stringent age restrictions to be used in determining
unaffected individuals which would increase the confidence
in any associations made. In the current sample the 90%
age restriction would be between 8 and 8.5 years for males
and 9 years for females. The use of these age restrictions in
the current sample would reduce the number of individuals
eligible to be included in the group to 13 which would reduce
the power of the genetic association tests still further.
The physiological functions of the DCM/AF associated
SNPs have not been confirmed, although some lie within
or close to genes [23]. Of the three SNPs associated with
DCM/AF in this current study only one, the intronic SNP
on chromosome 21 lies within a gene, PDE3B [23]. PDE3B
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has been shown to have a role in cardiac function [57,
58]. Of particular interest is that there has been reported
to be a difference in PDE3B mRNA expression between
males and females [59]. If PDE3B is involved in DCM/AF in
IWHs, the differential expression between males and females
could explain the difference in the age of onset between the
sexes. There were not enough unaffected individuals in the
current study to test the SNP for DCM/AF-association in
each sex separately. With the inclusion of additional affected
and unaffected individuals PDE3B could be a promising
candidate gene for identifying the function of one aspect of
the genetic basis of DCM in IWHs. The two other DCM/AF
associated SNPs are not within known genes [23]. These
SNPs could lie within regulatory regions or be in linkage
disequilibrium with regulatory regions or functional genetic
variants [60, 61]. Furtherwork is needed to establish themode
of action of these SNPs.
There are likely to be additional unidentified genetic sus-
ceptibility loci in IWH DCM/AF as there were affected
individuals with genotypes which appeared to confer a
lower risk of disease (Table 12). In addition, there may be
unidentified protective loci because there were unaffected
individualswith genotypes conferring a higher risk of disease,
although these individuals could develop disease later in life
as the age restrictions for inclusion in the unaffected group
were not very stringent. Further work with a larger number
of individuals is required to verify the current genetic associ-
ations and identify additional loci associatedwith IWHDCM
as in this study 72 cases and 23 controls were used across
a longitudinal study, but with a limited number of tested
markers and potential confounding effects such as cryptic
relatedness, further studies could provide further insights.
In addition, it was interesting to note that our marker allele
differed for many markers to that shown in a previous
study [23]; further examination of these affected areas could
elucidate the differences observed.
5. Conclusions
In conclusion, AF is related to DCM in the animals within
this study and this novel information enabled individuals
with both DCM and AF to be included in the affected group
for genetic association testing. In addition, male and female
IWHs were confirmed to have different ages of disease onset
which allowed more accurate allocation of individuals into
the unaffected group. This study also confirms our previous
work indicating that multiple loci analysis better predicts the
incidence of DCM than single loci alone; however, a larger
number of affected and unaffected individuals are required
to confirm the associations.
Competing Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
Acknowledgments
The authors are grateful to Jennifer Edwards (University
of Nottingham) for assistance with swab collection and
clinicians Dr. Angela Bodey from Abbey House Veterinary
Hospital, Jan Cormie from Cormie Referrals, and Sheena
Milne from North Downs Veterinary Group for useful
discussions. They would like to thank the owners of the Irish
Wolfhounds and the Irish Wolfhound Health Group who
enabled them to take swabs and completed health data. The
authors gratefully acknowledge generous funding from the
BBSRC University of Nottingham Doctoral Training Pro-
gramme BB/J014508/1 and the School of VeterinaryMedicine
and Science, University of Nottingham, awarded to Nigel P.
Mongan, Malcolm Cobb, and Catrin S. Rutland.
References
[1] A. Egenvall, B. N. Bonnett, and J. Ha¨ggstro¨m, “Heart disease as
a cause of death in insured Swedish dogs younger than 10 years
of age,” Journal of Veterinary Internal Medicine, vol. 20, no. 4,
pp. 894–903, 2006.
[2] A. C. Vollmar, “The prevalence of cardiomyopathy in the Irish
wolfhound: a clinical study of 500 dogs,” Journal of the American
Animal Hospital Association, vol. 36, no. 2, pp. 125–132, 2000.
[3] L. Mestroni, C. Rocco, D. Gregori et al., “Familial dilated
cardiomyopathy: evidence for genetic and phenotypic hetero-
geneity,” Journal of the American College of Cardiology, vol. 34,
no. 1, pp. 181–190, 1999.
[4] A. Posafalvi, J. C. Herkert, R. J. Sinke et al., “Clinical utility gene
card for: dilated cardiomyopathy (CMD),” European Journal of
Human Genetics, vol. 21, no. 10, p. 1185, 2013.
[5] O. Distl, A. C. Vollmar, C. Broschk, H. Hamann, and P. R.
Fox, “Complex segregation analysis of dilated cardiomyopathy
(DCM) in Irish wolfhounds,” Heredity, vol. 99, no. 4, pp. 460–
465, 2007.
[6] D. M. Dambach, A. Lannon, M. M. Sleeper, and J. Buchanan,
“Familial dilated cardiomyopathy of young Portuguese water
dogs,” Journal of Veterinary Internal Medicine, vol. 13, no. 1, pp.
65–71, 1999.
[7] A. D. Petric, P. Stabej, and A. Zemva, “Dilated cardiomyopathy
in doberman pinschers: survival, causes of death and a pedigree
review in a related line,” Journal of Veterinary Cardiology, vol. 4,
no. 1, pp. 17–24, 2002.
[8] T.-B. Mausberg, G. Wess, J. Simak et al., “A locus on chromo-
some 5 is associated with dilated cardiomyopathy in doberman
pinschers,” PLoS ONE, vol. 6, no. 5, Article ID e20042, 2011.
[9] N. G.Mahon, R. T.Murphy, C. A.MacRae, A. L. P. Caforio, P.M.
Elliott, and W. J. McKenna, “Echocardiographic evaluation in
asymptomatic relatives of patients with dilated cardiomyopathy
reveals preclinical disease,”Annals of InternalMedicine, vol. 143,
no. 2, pp. 108–115, 2005.
[10] T. W. Lewis, B. Abhayaratne, and S. C. Blott, “Trends in genetic
diversity for all Kennel Club registered pedigree dog breeds,”
Canine Genetics and Epidemiology, vol. 2, no. 1, pp. 1–10, 2015.
[11] V. J. Adams, K. M. Evans, J. Sampson, and J. L. N. Wood,
“Methods and mortality results of a health survey of purebred
dogs in the UK,” Journal of Small Animal Practice, vol. 51, no. 10,
pp. 512–524, 2010.
[12] A. Egenvall, A. Nødtvedt, and H. von Euler, “Bone tumors in
a population of 400 000 insured Swedish dogs up to 10 y of
age: incidence and survival,” Canadian Journal of Veterinary
Research, vol. 71, no. 4, pp. 292–299, 2007.
BioMed Research International 13
[13] C. M. Greenwell and P. H. Brain, “Aspiration pneumonia in
the Irish wolfhound: a possible breed predisposition,” Journal
of Small Animal Practice, vol. 55, no. 10, pp. 515–520, 2014.
[14] K. M. Evans and V. J. Adams, “Mortality and morbidity due
to gastric dilatation-volvulus syndrome in pedigree dogs in the
UK,” Journal of Small Animal Practice, vol. 51, no. 7, pp. 376–381,
2010.
[15] K. E. Mitchell, S. E. Boston, M. Kung et al., “Outcomes of limb-
sparing surgery using two generations of metal endoprosthesis
in 45 dogs with distal radial osteosarcoma. a veterinary society
of surgical oncology retrospective study,” Veterinary Surgery,
vol. 45, no. 1, pp. 36–43, 2016.
[16] J. Bhandal and S. E. Boston, “Pathologic fracture in dogs with
suspected or confirmed osteosarcoma,” Veterinary Surgery, vol.
40, no. 4, pp. 423–430, 2011.
[17] A. Vollmar and P. Fox, “Long-term outcome of irish wolfhound
dogs with preclinical cardiomyopathy, atrial fibrillation, or
both treated with pimobendan, benazepril hydrochloride, or
methyldigoxin monotherapy,” Journal of Veterinary Internal
Medicine, vol. 30, no. 2, pp. 553–559, 2016.
[18] C. Clercx, I. Reichler, D. Peeters et al., “Rhinitis/bronchop-
neumonia syndrome in irish wolfhounds,” Journal of Veterinary
Internal Medicine, vol. 17, no. 6, pp. 843–849, 2003.
[19] A. L. Leisewitz, J. A. Spencer, L. S. Jacobson, and H. Schroeder,
“Suspected primary immunodeficiency syndrome in three
related Irish wolfhounds,” Journal of Small Animal Practice, vol.
38, no. 5, pp. 209–212, 1997.
[20] L. T. Glickman, N. W. Glickman, D. B. Schellenberg, M.
Raghavan, and T. L. Lee, “Incidence of and breed-related risk
factors for gastric dilatation-volvulus in dogs,” Journal of the
American VeterinaryMedical Association, vol. 216, no. 1, pp. 40–
45, 2000.
[21] K. N. Adamik, I. A. Burgener, A. Kovacevic, S. P. Schulze, and
B. Kohn, “Myoglobin as a prognostic indicator for outcome in
dogs with gastric dilatation-volvulus,” Journal of Veterinary
Emergency and Critical Care, vol. 19, no. 3, pp. 247–253, 2009.
[22] B. N. Bonnett, A. Egenvall, A˚. Hedhammar, and P. Olson, “Mor-
tality in over 350,000 insured Swedish dogs from 1995–2000: I.
Breed-, gender-, age- and cause-specific rates,” Acta Veterinaria
Scandinavica, vol. 46, no. 3, pp. 105–120, 2005.
[23] U. Philipp, A. Vollmar, J. Ha¨ggstro¨m, A. Thomas, and O. Distl,
“Multiple loci are associated with dilated cardiomyopathy in
irish wolfhounds,” PLoS ONE, vol. 7, no. 6, Article ID e36691,
2012.
[24] K. M. Meurs, S. Lahmers, B. W. Keene et al., “A splice site muta-
tion in a gene encoding for PDK4, a mitochondrial protein, is
associated with the development of dilated cardiomyopathy in
the Doberman pinscher,” Human Genetics, vol. 131, no. 8, pp.
1319–1325, 2012.
[25] K. M. Meurs, J. A. Stern, D. D. Sisson et al., “Association of
dilated cardiomyopathy with the striatin mutation genotype in
boxer dogs,” Journal of Veterinary Internal Medicine, vol. 27, no.
6, pp. 1437–1440, 2013.
[26] P. Werner, M. G. Raducha, U. Prociuk, M. M. Sleeper, T. J.
Van Winkle, and P. S. Henthorn, “A novel locus for dilated
cardiomyopathymaps to canine chromosome 8,”Genomics, vol.
91, no. 6, pp. 517–521, 2008.
[27] M. Lynne O’Sullivan, M. R. O’Grady, W. Glen Pyle, and J. F.
Dawson, “Evaluation of 10 genes encoding cardiac proteins in
Doberman Pinschers with dilated cardiomyopathy,” American
Journal of Veterinary Research, vol. 72, no. 7, pp. 932–938, 2011.
[28] U. Philipp, A. Vollmar, andO.Distl, “Evaluation of six candidate
genes for dilated cardiomyopathy in Irish wolfhounds,” Animal
Genetics, vol. 39, no. 1, pp. 88–89, 2008.
[29] A. C.Wiersma, P. Stabej, P. A. J. Leegwater, B. A. VanOost,W. E.
Ollier, and J. Dukes-McEwan, “Evaluation of 15 candidate genes
for dilated cardiomyopathy in the Newfoundland dog,” Journal
of Heredity, vol. 99, no. 1, pp. 73–80, 2008.
[30] K. Lindblad-Toh, C. M. Wade, T. S. Mikkelsen et al., “Genome
sequence, comparative analysis and haplotype structure of the
domestic dog,” Nature, vol. 438, no. 7069, pp. 803–819, 2005.
[31] S. Simpson, J. Edwards, R. D. Emes, M. A. Cobb, N. P. Mongan,
and C. S. Rutland, “A predictive model for canine dilated
cardiomyopathy-a meta-analysis of Doberman Pinscher data,”
PeerJ, vol. 2015, no. 3, article e842, 2015.
[32] S. E. Brownlie and M. A. Cobb, “Observations on the develop-
ment of congestive heart failure in Irishwolfhoundswith dilated
cardiomyopathy,” Journal of Small Animal Practice, vol. 40, no.
8, pp. 371–377, 1999.
[33] M.W. S. Martin, M. J. Stafford Johnson, and B. Celona, “Canine
dilated cardiomyopathy: a retrospective study of signalment,
presentation and clinical findings in 369 cases,” Journal of Small
Animal Practice, vol. 50, no. 1, pp. 23–29, 2009.
[34] A. Tidholm and L. Jo¨nsson, “A retrospective study of canine
dilated cardiomyopathy (189 cases),” Journal of the American
Animal Hospital Association, vol. 33, no. 6, pp. 544–550, 1997.
[35] D. V. Unverferth, R. D. Magorien, M. L. Moeschberger, P. B.
Baker, J. K. Fetters, and C. V. Leier, “Factors influencing the
one-year mortality of dilated cardiomyopathy,” The American
Journal of Cardiology, vol. 54, no. 1, pp. 147–152, 1984.
[36] C. A. Wasywich, A. J. Pope, J. Somaratne, K. K. Poppe, G. A.
Whalley, and R. N. Doughty, “Atrial fibrillation and the risk
of death in patients with heart failure: a literature-based meta-
analysis,” Internal Medicine Journal, vol. 40, no. 5, pp. 347–356,
2010.
[37] C. A. Calvert, C. W. Pickus, G. J. Jacobs, and J. Brown, “Signal-
ment, survival, and prognostic factors in Doberman Pinschers
with end-stage cardiomyopathy,” Journal of Veterinary Internal
Medicine, vol. 11, no. 6, pp. 323–326, 1997.
[38] G. Wess, A. Schulze, V. Butz et al., “Prevalence of dilated
cardiomyopathy inDoberman Pinschers in various age groups,”
Journal of Veterinary Internal Medicine, vol. 24, no. 3, pp. 533–
538, 2010.
[39] U. Philipp, C. Broschk, A. Vollmar, and O. Distl, “Evaluation
of tafazzin as candidate for dilated cardiomyopathy in Irish
wolfhounds,” Journal of Heredity, vol. 98, no. 5, pp. 506–509,
2007.
[40] N. J. Camp, “Genomewide transmission/disequilibrium test-
ing—consideration of the genotypic relative risks at disease
loci,” American Journal of Human Genetics, vol. 61, no. 6, pp.
1424–1430, 1997.
[41] G. M. Clarke, C. A. Anderson, F. H. Pettersson, L. R. Cardon,
A. P. Morris, and K. T. Zondervan, “Basic statistical analysis in
genetic case-control studies,” Nature Protocols, vol. 6, no. 2, pp.
121–133, 2011.
[42] J. A.Morris andM. J. Gardner, “Calculating confidence intervals
for relative risks (odds ratios) and standardised ratios and rates,”
British Medical Journal, vol. 296, no. 6632, pp. 1313–1316, 1988.
[43] A. J. Morales, R. H. Haubricht, J. Y. Hwang, H. Asakura, and
S. S. C. Yen, “The effect of six months treatment with a 100mg
Daily Dose of Dehydroepiandrosterone (DHEA) on circulating
14 BioMed Research International
sex steroids, body composition and muscle strength in age-
advanced men and women,” Clinical Endocrinology, vol. 49, no.
4, pp. 421–432, 1998.
[44] J. M. Dabbs Jr., “Salivary testosterone measurements: reliability
across hours, days, and weeks,” Physiology and Behavior, vol. 48,
no. 1, pp. 83–86, 1990.
[45] M. M. Kushnir, T. Blamires, A. L. Rockwood et al., “Liq-
uid chromatography-tandem mass spectrometry assay for
androstenedione, dehydroepiandrosterone, and testosterone
with pediatric and adult reference intervals,”Clinical Chemistry,
vol. 56, no. 7, pp. 1138–1147, 2010.
[46] R. L. Rosenfield and P. Otto, “Androstenediol levels in human
peripheral plasma,” The Journal of Clinical Endocrinology and
Metabolism, vol. 35, no. 6, pp. 818–822, 1972.
[47] K. Lagergren, W. E. Ek, D. Levine et al., “Polymorphisms in
genes of relevance for oestrogen and oxytocin pathways and
risk of Barrett’s oesophagus and oesophageal adenocarcinoma:
a pooled analysis from the BEACON consortium,” PLoS ONE,
vol. 10, no. 9, Article ID 0138738, 2015.
[48] IWDB,The Irish Wolfhound Database, 2016.
[49] D. J. Hunter, P. Kraft, K. B. Jacobs et al., “A genome-wide
association study identifies alleles in FGFR2 associatedwith risk
of sporadic postmenopausal breast cancer,”Nature Genetics, vol.
39, no. 7, pp. 870–874, 2007.
[50] L. J. Scott, K. L.Mohlke, L. L. Bonnycastle et al., “A genome-wide
association study of type 2 diabetes in finns detects multiple
susceptibility variants,” Science, vol. 316, no. 5829, pp. 1341–1345,
2007.
[51] K. Litchfield, R. Sultana, A. Renwick et al., “Multi-stage
genome-wide association study identifies new susceptibility
locus for testicular germ cell tumour on chromosome 3q25,”
Human Molecular Genetics, vol. 24, no. 4, pp. 1169–1176, 2015.
[52] I. Cleynen, G. Boucher, L. Jostins et al., “Inherited determinants
of Crohn’s disease and ulcerative colitis phenotypes: A Genetic
Association Study,” The Lancet, vol. 387, no. 10014, pp. 156–167,
2016.
[53] D. W. Belsky, T. E. Moffitt, K. Sugden et al., “Development and
evaluation of a genetic risk score for obesity,” Biodemography
and Social Biology, vol. 59, no. 1, pp. 85–100, 2013.
[54] S. Ripatti, E. Tikkanen, M. Orho-Melander et al., “A multilocus
genetic risk score for coronary heart disease: case-control and
prospective cohort analyses,”The Lancet, vol. 376, no. 9750, pp.
1393–1400, 2010.
[55] C. A. Ibrahim-Verbaas, M. Fornage, J. C. Bis et al., “Predicting
stroke through genetic risk functions: the CHARGE risk score
project,” Stroke, vol. 45, no. 2, pp. 403–412, 2014.
[56] Z. Ye, E. Austin, D. J. Schaid, and I. J. Kullo, “A multi-locus
genetic risk score for abdominal aortic aneurysm,” Atheroscle-
rosis, vol. 246, pp. 274–279, 2016.
[57] D. Palmer and D. H. Maurice, “Dual expression and differential
regulation of phosphodiesterase 3A and phosphodiesterase 3B
in human vascular smooth muscle: implications for phos-
phodiesterase 3 inhibition in human cardiovascular tissues,”
Molecular Pharmacology, vol. 58, no. 2, pp. 247–252, 2000.
[58] Y. W. Chung, C. Lagranha, Y. Chen et al., “Targeted dis-
ruption of PDE3B, but not PDE3A, protects murine heart
from ischemia/reperfusion injury,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 112, no.
17, pp. E2253–E2262, 2015.
[59] J. Wang, S. Bingaman, and V. H. Huxley, “Intrinsic sex-
specific differences in microvascular endothelial cell phos-
phodiesterases,” American Journal of Physiology—Heart and
Circulatory Physiology, vol. 298, no. 4, pp. H1146–H1154, 2010.
[60] L. Guo, Y. Du, S. Chang, K. Zhang, and J. Wang, “RSNPBase: a
database for curated regulatory SNPs,” Nucleic Acids Research,
vol. 42, no. 1, pp. D1033–D1039, 2014.
[61] M. A. Schaub, A. P. Boyle, A. Kundaje, S. Batzoglou, and M.
Snyder, “Linking disease associations with regulatory informa-
tion in the human genome,”Genome Research, vol. 22, no. 9, pp.
1748–1759, 2012.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
